These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 10213223

  • 1. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models.
    Rosenblum MG, Shawver LK, Marks JW, Brink J, Cheung L, Langton-Webster B.
    Clin Cancer Res; 1999 Apr; 5(4):865-74. PubMed ID: 10213223
    [Abstract] [Full Text] [Related]

  • 2. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
    Cao Y, Marks JD, Marks JW, Cheung LH, Kim S, Rosenblum MG.
    Cancer Res; 2009 Dec 01; 69(23):8987-95. PubMed ID: 19934334
    [Abstract] [Full Text] [Related]

  • 3. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
    Xu F, Leadon SA, Yu Y, Boyer CM, O'Briant K, Ward K, McWatters A, Zhao X, Bae DS, DeSombre K, Zalutsky MR, Bast RC.
    Clin Cancer Res; 2000 Aug 01; 6(8):3334-41. PubMed ID: 10955821
    [Abstract] [Full Text] [Related]

  • 4. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain.
    Masui H, Kamrath H, Apell G, Houston LL, Mendelsohn J.
    Cancer Res; 1989 Jul 01; 49(13):3482-8. PubMed ID: 2786451
    [Abstract] [Full Text] [Related]

  • 5. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.
    Horak E, Hartmann F, Garmestani K, Wu C, Brechbiel M, Gansow OA, Landolfi NF, Waldmann TA.
    J Nucl Med; 1997 Dec 01; 38(12):1944-50. PubMed ID: 9430475
    [Abstract] [Full Text] [Related]

  • 6. An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors.
    Scott CF, Goldmacher VS, Lambert JM, Jackson JV, McIntyre GD.
    J Natl Cancer Inst; 1987 Nov 01; 79(5):1163-72. PubMed ID: 3500356
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of human tumor growth by intraperitoneal immunotoxins in nude mice.
    Marks A, Ettenson D, Bjorn MJ, Lei M, Baumal R.
    Cancer Res; 1990 Jan 15; 50(2):288-92. PubMed ID: 2295069
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetic analysis of immunotoxin uptake in solid tumors: role of plasma kinetics, capillary permeability, and binding.
    Sung C, Youle RJ, Dedrick RL.
    Cancer Res; 1990 Nov 15; 50(22):7382-92. PubMed ID: 2224866
    [Abstract] [Full Text] [Related]

  • 9. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
    Tolmachev V, Orlova A, Pehrson R, Galli J, Baastrup B, Andersson K, Sandström M, Rosik D, Carlsson J, Lundqvist H, Wennborg A, Nilsson FY.
    Cancer Res; 2007 Mar 15; 67(6):2773-82. PubMed ID: 17363599
    [Abstract] [Full Text] [Related]

  • 10. Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin.
    Rosenblum MG, Marks JW, Cheung LH.
    Cancer Chemother Pharmacol; 1999 Mar 15; 44(4):343-8. PubMed ID: 10447583
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo.
    Yang D, Kuan CT, Payne J, Kihara A, Murray A, Wang LM, Alimandi M, Pierce JH, Pastan I, Lippman ME.
    Clin Cancer Res; 1998 Apr 15; 4(4):993-1004. PubMed ID: 9563895
    [Abstract] [Full Text] [Related]

  • 13. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
    Griffin T, Raso V.
    Cancer Res; 1991 Aug 15; 51(16):4316-22. PubMed ID: 1868454
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel.
    Mohamedali KA, Poblenz AT, Sikes CR, Navone NM, Thorpe PE, Darnay BG, Rosenblum MG.
    Cancer Res; 2006 Nov 15; 66(22):10919-28. PubMed ID: 17108129
    [Abstract] [Full Text] [Related]

  • 15. Comparison of growth inhibition of a human ovarian adenocarcinoma cell line by free monoclonal antibodies and their corresponding antibody-recombinant ricin A chain immunotoxins.
    Ettenson D, Sheldon K, Marks A, Houston LL, Baumal R.
    Anticancer Res; 1988 Nov 15; 8(4):833-8. PubMed ID: 3263079
    [Abstract] [Full Text] [Related]

  • 16. A caspase-6 and anti-HER2 antibody chimeric tumor-targeted proapoptotic molecule decreased metastasis of human osteosarcoma.
    Wang LF, Zhou Y, Xu YM, Qiu XC, Zhou BG, Wang F, Long H, Chen X, Yang TT, Ma BA, Fan QY, Yang AG.
    Cancer Invest; 2009 Aug 15; 27(7):774-80. PubMed ID: 19488908
    [Abstract] [Full Text] [Related]

  • 17. Suppression of an epidermal growth factor receptor-hyperproducing tumor by an immunotoxin conjugate of gelonin and a monoclonal anti-epidermal growth factor receptor antibody.
    Hirota N, Ueda M, Ozawa S, Abe O, Shimizu N.
    Cancer Res; 1989 Dec 15; 49(24 Pt 1):7106-9. PubMed ID: 2555059
    [Abstract] [Full Text] [Related]

  • 18. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody.
    Melani C, Figini M, Nicosia D, Luison E, Ramakrishna V, Casorati G, Parmiani G, Eshhar Z, Canevari S, Colombo MP.
    Cancer Res; 1998 Sep 15; 58(18):4146-54. PubMed ID: 9751627
    [Abstract] [Full Text] [Related]

  • 19. In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice.
    Penichet ML, Challita PM, Shin SU, Sampogna SL, Rosenblatt JD, Morrison SL.
    Lab Anim Sci; 1999 Apr 15; 49(2):179-88. PubMed ID: 10331548
    [Abstract] [Full Text] [Related]

  • 20. Development of resistance to cisplatin is associated with decreased expression of the gp185c-erbB-2 protein and alterations in growth properties and responses to therapy in an ovarian tumor cell line.
    Langton-Webster BC, Xuan JA, Brink JR, Salomon DS.
    Cell Growth Differ; 1994 Dec 15; 5(12):1367-72. PubMed ID: 7696185
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.